Andrew Cheng - 16 Aug 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President and CEO, Director
Signature
Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
16 Aug 2024
Net transactions value
+$15,091
Form type
4
Filing time
20 Aug 2024, 11:45:48 UTC
Previous filing
02 Jul 2024
Next filing
13 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $15,091 +24,538 +4.2% $0.6150 607,155 16 Aug 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -24,538 -100% $0.000000 0 16 Aug 2024 Common Stock 24,538 $0.6150 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are vested and currently exercisable.